Abstract 532P
Background
Immune checkpoint inhibitors (ICIs) have come to be used for the treatment of the patients with malignant pleural mesothelioma (MPM). Although modified RECIST (mRECIST) criteria is the standard method to evaluate the antitumor efficacy of ICIs, it is sometimes difficult to distinguish progressive disease from pseudoprogression (PsPD). While serum soluble mesothelin related peptide (SMRP) is commonly known as a specific tumor marker of MPM, the significance of SMRP levels in determining the efficacy of ICI treatment has not been established.
Methods
We investigated the relationship between changes of serum SMRP levels and treatment response in MPM patients treated with ipilimumab plus nivolumab combination therapy at our hospital between June 2021 and January 2023.
Results
Twenty-eight patients were included in the study. Median age was 75 years (59-85). The number of histological subtypes of epithelioid, sarcomatoid, biphasic and desmoplastic were 18, 6, 3 and 1, respectively. Treatment response was evaluated by mRECIST. The number of patients who achieved partial response (PR), stable disease (SD) and progressive disease (PD) were 9, 16 and 3, respectively. Among 25 patients with PR and SD, PsPD was observed in 5 patients (PR/SD: 3/2). The median serum SMRP before treatment in all patients was 0.90 nmol/L (0.4 - 16.9)., and the change from baseline at the time of first evaluation was +0.1 nmol/L (-4.5 - +24.5), The median change of serum SMRP level from baseline in patients with PR, SD, PsPD and PD was 0.0 nmol/L (-1.0 - +1.4), +0.1 nmol/L (-4.5 - +4.5), +0.2 nmol/L (-0.9 - +0.9) and +19.5 nmol/L (+0.1 - +24.5), respectively. These results indicated that serum SMRP level in patients with PD already tended to increase at the time of first evaluation.
Conclusions
Our results suggested that changes in serum SMRP levels was useful in determining the efficacy of ICI treatment. We are planning to accumulate more cases in the future for further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract